Ausbil Investment Management Ltd Has $1.23 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ausbil Investment Management Ltd cut its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 63.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 13,246 shares of the medical instruments supplier's stock after selling 22,740 shares during the quarter. Ausbil Investment Management Ltd owned 0.06% of LeMaitre Vascular worth $1,230,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Conestoga Capital Advisors LLC grew its holdings in LeMaitre Vascular by 0.4% during the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier's stock worth $159,747,000 after acquiring an additional 8,584 shares during the period. Vanguard Group Inc. raised its holdings in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier's stock worth $103,112,000 after purchasing an additional 4,964 shares in the last quarter. Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 1.0% during the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after purchasing an additional 11,318 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after buying an additional 90,573 shares in the last quarter. Finally, Summit Creek Advisors LLC grew its position in LeMaitre Vascular by 0.6% in the first quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier's stock worth $15,259,000 after buying an additional 1,435 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 0.4 %

Shares of LMAT traded down $0.39 during trading hours on Thursday, reaching $86.58. The company's stock had a trading volume of 96,665 shares, compared to its average volume of 121,922. The company has a 50 day moving average of $89.22 and a two-hundred day moving average of $81.97. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of 57.60, a P/E/G ratio of 2.45 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. During the same quarter in the prior year, the firm earned $0.37 EPS. The company's revenue was up 11.4% compared to the same quarter last year. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 20th. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a "buy" rating and a $105.00 price target on the stock. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective for the company. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Tuesday, August 27th. Finally, Barrington Research restated an "outperform" rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.67.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company's stock, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.